drugset / Trial / NCT05571163

A Study to Evaluate the Relative Bioavailability of AMG 510 Administered as Tablets and as a Water Dispersion in Healthy Participants

NCT05571163

Phase 1 Completed 13 enrolled Amgen
RandomizedCrossoverOpen-labelBasic science

Summary

The primary objective of the study is to evaluate the pharmacokinetics (PK) of AMG 510 administered as 8 x 120-mg tablets and as water dispersion in healthy participants.

Timeline

Start
2020-03-06
Primary completion
2020-06-14
Completion
2020-06-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Sotorasib Small molecule 960 mg Oral

Indications

No indication recorded.